BioNTech Investor Day Presentation Deck

Multi-platform strategy Technology-agnostic innovation engine ● ● ● ● ● mRNA vaccines Individualized cancer vaccines (iNeST) Off-the-shelf cancer vaccines (FixVac) Antigen-specific tolerance vaccines Prophylactic infectious disease vaccines CAR T cells Individualized TCR therapies Polyspecific T-cell therapies • In vivo engineered cell therapies Cell & gene therapies BIONTECH • Against highly selective cancer cell surface antigens for high precision Targeted antibodies Selective TLR 7 antagonism ● Small molecule immunomodulators Next-generation immunomodulators Targeting immune checkpoint molecules Multiple product classes with unique combination potential Multi-platform engine Engineered bispecific antibodies Engineered mechanisms of action ● D 111 D mRNA-encoded cytokines (RiboCytokines) mRNA-encoded antibodies (RiboMabs) mRNA-encoded lysins (RiboLysins) Ribologicals BIONTECH 28

View entire presentation